Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting1
Terminated1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

recruiting125%
terminated125%
unknown125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

NCT04789044
unknown

NTX-001 to Repair Peripheral Nerve Transection(s)

NCT05565846
completedphase_2

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

NCT04572906
terminatedphase_2

A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

NCT05293522

Clinical Trials (4)

Showing 4 of 4 trials
NCT04789044Phase 2

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

Recruiting
NCT05565846

NTX-001 to Repair Peripheral Nerve Transection(s)

Unknown
NCT04572906Phase 2

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

Completed
NCT05293522Phase 2

A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4